Abstract: Ready-to-use (RTU) Sodium Phosphates solutions for phosphorus replacement therapy are presented that include Sodium phosphate with/without sodium chloride at a fixed volume with 6 to 15 mmol/100 mL phosphorus, no more than 20 mEq/100 mL Sodium and less than 25 mcg/L aluminum.

Abstract: Compositions of a stabilized chlorthalidone suspension and methods for making a stabilized chlorthalidone suspension include chlorthalidone along with a solubilizing and/or wetting agent, a suspending agent, and a viscosity increasing agent and/or an anti-caking agent, wherein the stabilized chlorthalidone suspension is a uniform dispersion with consistent concentration of chlorthalidone throughout the composition and storage.

Abstract: Ready-to-use (RTU) Sodium Phosphates solutions for phosphorus replacement therapy are presented that include Sodium phosphate with/without sodium chloride at a fixed volume with 1.5 to 15 mmol/100 mL phosphorus, no more than 20 mEq/100 mL Sodium and less than 50 mcg/L aluminum.

Abstract: A spray-dried storage stable pantoprazole composition is provided. The pantoprazole composition includes a pantoprazole and an excipient matrix including sodium chloride (NaCl). The pantoprazole is substantially uniformly dispersed in the excipient matrix. A method for forming a storage stable pantoprazole composition is also provided. The method includes combining a bulking agent and water to form a first solution, combining a pantoprazole and the first solution to form a second solution, combining sodium hydroxide and the second solution to form a bulk solution, and removing water from the bulk solution by drying to form the storage stable pantoprazole composition.

Abstract: Compositions of a stabilized chlorthalidone suspension and methods for making a stabilized chlorthalidone suspension include chlorthalidone along with a solubilizing and/or wetting agent, a suspending agent, and a viscosity increasing agent and/or an anti-caking agent, wherein the stabilized chlorthalidone suspension is a uniform dispersion with consistent concentration of chlorthalidone throughout the composition and storage.

Abstract: Ready-to-use (RTU) potassium phosphates solutions for phosphorus replacement therapy are presented that include potassium phosphate and sodium chloride at a fixed volume with 1.5 to 15 mmol/100 mL phosphorus, no more than 22 mEq/100 mL potassium and less than 50 mcg/L aluminum.

Abstract: A composition of, method for producing, and use of an amorphous lyophilized Phenobarbital Sodium having high purity are presented. The amorphous lyophilized Phenobarbital Sodium is storage-stable being essentially void of impurities (e.g., phenylethylacetylurea (PEAU), 2-ethyl-2-phenylmalonamide (2EPMM), and/or alpha-phenylbutyrylguanidine (PBG)) upon reconstitution in water.

Abstract: Ready-to-use (RTU) potassium phosphates solutions for phosphorus replacement therapy are presented that include potassium phosphate and sodium chloride at a fixed volume with 1.5 to 15 mmol/100 mL phosphorus, no more than 22 mEq/100 mL potassium and less than 50 mcg/L aluminum.

Abstract: A ready-to-use (RTU) potassium phosphates in sodium chloride solution for phosphorus replacement therapy includes potassium phosphate and sodium chloride at a fixed volume with 15 mmol/100 mL phosphorus and 22 mEq/100 mL potassium and less than 50 mcg/L aluminum.

Abstract: Described is an aqueous calcium gluconate solution formulated without calcium saccharate, which can be stored in a flexible plastic bag and can be terminally sterilized.

Abstract: A composition of, method for producing, and use of an amorphous lyophilized Phenobarbital Sodium having high purity are presented. The amorphous lyophilized Phenobarbital Sodium is storage-stable being essentially void of impurities (e.g., phenylethylacetylurea (PEAU), 2-ethyl-2-phenylmalonamide (2EPMM), and/or alpha-phenylbutyrylguanidine (PBG)) upon reconstitution in water.

Abstract: Described is an aqueous calcium gluconate solution formulated without calcium saccharate, which can be stored in a flexible plastic bag and can be terminally sterilized.

Abstract: A composition of, method for producing, and use of an amorphous lyophilized Phenobarbital Sodium having high purity are presented. The amorphous lyophilized Phenobarbital Sodium is storage-stable being essentially void of impurities (e.g., phenyl ethylacetylurea (PEAU), 2-ethyl-2-phenylmalonamide (2EPMM), and/or alpha-phenylbutyrylguanidine (PBG)) upon reconstitution in water.

Abstract: A composition of, method for producing, and use of an amorphous lyophilized Phenobarbital Sodium having high purity are presented. The amorphous lyophilized Phenobarbital Sodium is storage-stable being essentially void of impurities (e.g., phenylethylacetylurea (PEAU), 2-ethyl-2-phenylmalonamide (2EPMM), and/or alpha-phenylbutyrylguanidine (PBG)) upon reconstitution in water.

Abstract: A ready-to-use (RTU) potassium phosphates in sodium chloride solution for phosphorus replacement therapy includes potassium phosphate and sodium chloride at a fixed volume with 15 mmol/100 mL phosphorus and 22 mEq/100 mL potassium and less than 50 mcg/L aluminum.

Abstract: A spray-dried storage stable pantoprazole composition is provided. The pantoprazole composition includes a pantoprazole and an excipient matrix including sodium chloride (NaCl). The pantoprazole is substantially uniformly dispersed in the excipient matrix. A method for forming a storage stable pantoprazole composition is also provided. The method includes combining a bulking agent and water to form a first solution, combining a pantoprazole and the first solution to form a second solution, combining sodium hydroxide and the second solution to form a bulk solution, and removing water from the bulk solution by drying to form the storage stable pantoprazole composition.

Abstract: Compositions of a stabilized chlorthalidone suspension and methods for making a stabilized chlorthalidone suspension include chlorthalidone along with a solubilizing and/or wetting agent, a suspending agent, and a viscosity increasing agent and/or an anti-caking agent, wherein the stabilized chlorthalidone suspension is a uniform dispersion with consistent concentration of chlorthalidone throughout the composition and storage.

Abstract: A composition of, method for producing, and use of an amorphous lyophilized Phenobarbital Sodium having high purity are presented. The amorphous lyophilized Phenobarbital Sodium is storage-stable being essentially void of impurities (e.g., phenylethylacetylurea (PEAU), 2-ethyl-2-phenylmalonamide (2EPMM), and/or alpha-phenylbutyrylguanidine (PBG)) upon reconstitution in water.